| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 12/19/2013 | US20130337042 Use of PVP-Iodine Liposomes for Treatment of Herpes |
| 12/19/2013 | US20130337041 Charged phospholipid compositions and methods for their use |
| 12/19/2013 | US20130337036 Method of using fibrous tissue sealant |
| 12/19/2013 | US20130337033 Nitric oxide-releasing compositions and methods |
| 12/19/2013 | US20130337032 Topical Patch For Pain Relief Using Cooling Agent |
| 12/19/2013 | US20130337031 Topical formulations, systems and methods |
| 12/19/2013 | US20130337027 Medical Devices and Implements with Liquid-Impregnated Surfaces |
| 12/19/2013 | US20130337022 Pharmaceutical dosage form |
| 12/19/2013 | US20130337020 Pharmaceutical Compositions |
| 12/19/2013 | US20130337006 Polyanionic polymer adjuvants for haemophilus influenzae b saccharide vaccines |
| 12/19/2013 | US20130336928 Methods and pharmaceutical compositions for treatment of central nervous system disorders with therapeutic agent(s) in patients with concurrent non-cns condition(s) or disorders contraindicating systemic administration of the therapeutic agent(s) |
| 12/19/2013 | US20130336892 Chimeric t1r taste receptor polypeptides and nucleic acid sequences encoding and cell lines that express said chimeric t1r polypeptides |
| 12/19/2013 | US20130336891 Formulation of acoustically activatable particles having low vaporization energy and methods for using same |
| 12/19/2013 | US20130336884 Nanoparticle fabrication methods, systems, and materials for fabricating artificial red blood cells |
| 12/19/2013 | DE112012001386T5 Optimierte Präparate von sehr anpassungsfähigen Aggregaten Optimized preparation of highly adaptable aggregates |
| 12/19/2013 | DE112012001382T5 Arzneimittelfreie Zusammensetzungen und Methoden zur Verminderung von peripheren Entzündungen und Schmerzen Drug-free compositions and methods for the reduction of peripheral inflammation and pain |
| 12/19/2013 | DE102010023850B4 Funktionalisierte Nanopartikel mit verbesserter Bioverfügbarkeit Functionalized nanoparticles with improved bioavailability |
| 12/19/2013 | CA2877715A1 Topical ophthalmological pharmaceutical composition containing axitinib |
| 12/19/2013 | CA2877710A1 Topical ophthalmological pharmaceutical composition containing pazopanib |
| 12/19/2013 | CA2877678A1 Topical ophthalmological pharmaceutical composition containing cediranib |
| 12/19/2013 | CA2876902A1 Compositions and methods for transmucosal absorption |
| 12/19/2013 | CA2876739A1 Pharmaceutical composition containing phosphate binding polymer |
| 12/19/2013 | CA2876656A1 Cationic lipid vaccine compositions and methods of use |
| 12/19/2013 | CA2876540A1 A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota |
| 12/19/2013 | CA2876474A1 Polymeric treatment compositions |
| 12/19/2013 | CA2876403A1 Desethylamiodarone compositions |
| 12/19/2013 | CA2876371A1 Prophylactic and/or therapeutic agent for mild cognitive impairment |
| 12/19/2013 | CA2876311A1 Topical ophthalmological pharmaceutical composition containing sunitinib |
| 12/19/2013 | CA2876283A1 Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same |
| 12/19/2013 | CA2876070A1 Method of preparing a composition based on hyaluronic acid |
| 12/19/2013 | CA2876062A1 Effervescent dosage form |
| 12/19/2013 | CA2875824A1 Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| 12/19/2013 | CA2875470A1 Tailored liposomes for the treatment of bacterial infections |
| 12/19/2013 | CA2875386A1 Antibody formulation |
| 12/19/2013 | CA2875206A1 Nanoceria for the treatment of oxidative stress |
| 12/19/2013 | CA2875198A1 Compounds for treating inflammation and pain |
| 12/19/2013 | CA2840372A1 Method for producing powders for inhalation |
| 12/18/2013 | EP2674166A1 Use of erythropoietin (EPO) for the local treatment of cancer treatment-associated osteo-necrosis of the jaw |
| 12/18/2013 | EP2674158A1 Treatment and prevention of cardiac arrhythmias |
| 12/18/2013 | EP2674154A2 Sildenafil-free base-containing film preparation and method for producing same |
| 12/18/2013 | EP2674153A1 Bendroflumethiazide-containing controlled release pharmaceutical formulations |
| 12/18/2013 | EP2674152A1 Stable liquid oily ready-to-use formulations, preparation thereof and use thereof |
| 12/18/2013 | EP2674150A1 Pharmaceutical preparation with improved agent stability |
| 12/18/2013 | EP2674149A1 Method for preparing composite granule comprising low-substituted hydroxypropyl cellulose and rapid release preparation |
| 12/18/2013 | EP2673413A1 Cationic microparticles and use in the field of cosmetotextiles |
| 12/18/2013 | EP2673079A2 Layered bodies, compositions containing them and processes for producing them |
| 12/18/2013 | EP2673020A1 Dual drug pen-injection device with micro-reservoirs carrying secondary drug for emergency injection |
| 12/18/2013 | EP2673006A2 Method of preparing iron oxide nanoparticles coated with hydrophilic material, and magnetic resonance imaging contrast agent using the same |
| 12/18/2013 | EP2672985A1 Citrate free pharmaceutical compositions comprising anakinra |
| 12/18/2013 | EP2672981A1 Multiparticulate l-menthol formulations and related methods |
| 12/18/2013 | EP2672970A2 Forms of rifaximin and uses thereof |
| 12/18/2013 | EP2672968A1 Econazole composition and methods of treatment therewith |
| 12/18/2013 | EP2672962A1 Novel antifungal composition |
| 12/18/2013 | EP2672961A1 Effervescent gamma-hydroxybutyric acid granules |
| 12/18/2013 | EP2672960A1 Pharmaceutical composition comprising tadalafil and a cyclodextrin |
| 12/18/2013 | EP2672959A1 Granulated composition comprising tadalafil and a disintegrant |
| 12/18/2013 | EP2672958A1 Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia |
| 12/18/2013 | EP2672957A1 Novel composition for the treatment of cystic fibrosis |
| 12/18/2013 | EP2672956A1 Novel formulations for dermal, transdermal and mucosal use 1 |
| 12/18/2013 | EP2672955A1 Storage-stable formulation of paracetamol in aqueous solution |
| 12/18/2013 | EP2672953A1 Artificial oil bodies |
| 12/18/2013 | EP2672950A1 Anti-inflammatory effect of microfibrillated cellulose |
| 12/18/2013 | EP2672849A1 Systems and methods of cosmeto-compression apparel |
| 12/18/2013 | EP2446882B1 Medicament with improved storage stability containing the active ingredient hydromorphone |
| 12/18/2013 | EP2335705B1 Use of sphingomyelin for the treatment of influenza |
| 12/18/2013 | EP2331079B1 Pharmaceutical formulation |
| 12/18/2013 | EP2314327B1 Injectable cross-linked polymeric preparations and uses thereof |
| 12/18/2013 | EP2310018B1 Use of nifurtimox for treating giardiasis |
| 12/18/2013 | EP2265263B1 Chewing composition and the use thereof |
| 12/18/2013 | EP2240160B1 Lubricant mousse |
| 12/18/2013 | EP2165715B1 Therapeutic agent for cancer, and method for treatment of cancer |
| 12/18/2013 | EP2073795B1 Abuse resistant drug formulation |
| 12/18/2013 | EP2030642B1 Protein gel and process for its preparation |
| 12/18/2013 | EP1926473B1 Antimicrobial preparations having a content of octenidine dihydrochloride encapsulated in liposomes |
| 12/18/2013 | EP1919295B1 Coated chewable confection |
| 12/18/2013 | EP1814527B1 Bilayer tablet comprising telmisartan and amlodipine |
| 12/18/2013 | EP1748762B1 Dosage form obtainable from a mixture of powders containing an inorganic pigment |
| 12/18/2013 | EP1542661B1 Modified release dosage form with two cores |
| 12/18/2013 | EP1452174B1 Stabilized composition comprising reduced coenzyme q10 |
| 12/18/2013 | EP1283704B1 Pharmaceutical compositions for transdermal administration of anti-inflammatory agents |
| 12/18/2013 | CN203342089U Arnebia root oil-immersed spunlace nonwoven fabric paste for external use |
| 12/18/2013 | CN203342063U Contraceptive patch |
| 12/18/2013 | CN203342062U Angelica sinensis volatile oil transdermal absorption paste |
| 12/18/2013 | CN203342046U Constant-volume program-controlled plaster spreader |
| 12/18/2013 | CN1899277B Composition of rheinic acid or rheinic acid compounds, its preparing method and its use in preparing medicine for treating diabetic nephrosis |
| 12/18/2013 | CN103459542A Adhesive composition comprising tannin, polyethylene glycol, and water, lower alcohol or mixture thereof |
| 12/18/2013 | CN103458971A Composition containing a cellulose, a vegetable oil and a volatile solvent, and use thereof as a dressing |
| 12/18/2013 | CN103458929A Fat emulsion containing prostaglandin |
| 12/18/2013 | CN103458921A Spray dried myrosinase and use to produce isothiocyanates |
| 12/18/2013 | CN103458914A Skin wound healing compositions and methods of use thereof |
| 12/18/2013 | CN103458906A Process for preparation of a herbal extract |
| 12/18/2013 | CN103458903A Radiopaque embolic particles |
| 12/18/2013 | CN103458902A Therapeutic use of a tlr agonist and combination therapy |
| 12/18/2013 | CN103458901A Oral dosage forms for modified release comprising tasocitinib |
| 12/18/2013 | CN103458900A Stable compositions of tetrahydrobiopterin |
| 12/18/2013 | CN103458897A Pharmaceutical cream compositions of oxymetazoline for treating symptoms of rosacea |
| 12/18/2013 | CN103458895A Compositions of rotigotine, derivatives thereof, or pharmaceutically acceptable salts of rotigotine or its derivative |
| 12/18/2013 | CN103458894A High concentration olopatadine ophthalmic composition |
| 12/18/2013 | CN103458880A Unit dose form for oral administration |
| 12/18/2013 | CN103458879A Osmotic mediated release synthetic nanocarriers |